[Somatostatin receptor scintigraphy].
Somatostatin receptor scintigraphy (SRS) is a very valuable imaging technique for visualisation of a diversity of neuroendocrine tumours. The sensitivity for localisation of carcinoid tumours is high, but somewhat lower for other neuroendocrine tumours. The methodology, multiple clinical aspects and limitations of the examination are described. The value of the method in patients with non-neuroendocrine tumours has yet to be established. The development of new radio-labelled somatostatin analogues for diagnosis and treatment is briefly discussed.
Rasmussen
Karin
K
Arhus Sygehus, Afdeling for Klinisk Fysiologi og Nuklearmedicin, Arhus C. karinr@dadlnet.dk
Nielsen
Jørn Theil
JT
Rehling
Michael
M
D004701:Endocrine Gland Neoplasms / Q000000981:diagnostic imaging*; D006801:Humans; D007205:Indium Radioisotopes; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin / Q000378:metabolism; D012680:Sensitivity and Specificity; D013004:Somatostatin / Q000031:analogs & derivatives
D007205:Indium Radioisotopes; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin; D013004:Somatostatin